This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.
-
Profit before tax SEK 935m (2,047)
-
Earnings per share before dilution SEK 2.21 (4.93)
-
Mixed development in the holdings - half with positive trend, half less favourable development
-
Add-on acquisition of Sophion Bioscience
-
Medisize sold - exit gain SEK 38m
-
Total return on Ratos shares -33%
All information related to the interim report can be found here..
Stockholm 9 November 2011
Ratos AB (publ)
For further information:
Arne Karlsson, CEO, +46 8 700 17 00
Emma Rheborg, Head of Corporate Communications & IR, +46 8 700 17 20